GRAFT VERSUS HOST DISEASE (GVHD)
INCYTE (INCY) HAS SEVERAL GOOD NEWS. As a matter of fact, Incyte has exciting news coming from innumerable activities strategized by the firm’s dynamic management. The first good news came from the FDA, granting Breakthrough Therapy Designation for Jakafi® (ruxolitinib) for the treatment of patients with acute graft-versus-host disease (GVHD). There are currently no approved treatments for GVHD.

Breakthrough Therapy Designation is awarded to treatments expected to make a difference in the lives of people. The breakthrough designated product has the opportunity to   be . . .